IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.202
NA - Nord America 1.943
AS - Asia 598
OC - Oceania 2
SA - Sud America 1
Totale 4.746
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.928
IE - Irlanda 492
CN - Cina 487
IT - Italia 450
SE - Svezia 381
FI - Finlandia 371
DE - Germania 157
UA - Ucraina 124
AT - Austria 79
TR - Turchia 65
BE - Belgio 51
FR - Francia 28
GB - Regno Unito 26
IN - India 23
CA - Canada 15
NL - Olanda 12
CZ - Repubblica Ceca 8
VN - Vietnam 8
IR - Iran 7
PL - Polonia 5
HU - Ungheria 4
JP - Giappone 4
LU - Lussemburgo 3
RO - Romania 3
CH - Svizzera 2
ES - Italia 2
NZ - Nuova Zelanda 2
RU - Federazione Russa 2
SG - Singapore 2
HR - Croazia 1
KR - Corea 1
PE - Perù 1
SI - Slovenia 1
TW - Taiwan 1
Totale 4.746
Salva come PNG Salva come JPEG
Città #
Dublin 492
Chandler 408
Ann Arbor 338
Parma 158
Dearborn 155
Jacksonville 144
Beijing 95
Nanjing 84
Princeton 67
Vienna 66
Izmir 65
Bremen 61
Brussels 44
Nanchang 40
San Mateo 40
Shenyang 37
Ashburn 36
Wilmington 34
Boardman 30
Helsinki 30
Kunming 28
Hebei 27
Hefei 25
Jinan 23
Des Moines 22
Modena 22
Redmond 20
Tianjin 17
Woodbridge 17
Los Angeles 16
Norwalk 14
Milan 13
Jiaxing 12
Neviano degli Arduini 12
Wayne 12
Leawood 11
Changsha 10
Fremont 10
Toronto 9
Amsterdam 8
Dong Ket 8
Fuzhou 8
Grafing 8
Guangzhou 8
Ardabil 7
Augusta 7
Leuven 7
Chengdu 6
Follonica 6
Monmouth Junction 6
Redwood City 6
Rome 6
Zhengzhou 6
Fairfield 5
Ningbo 5
Seattle 5
Gainesville 4
Haikou 4
Houston 4
Reggio Emilia 4
Soliera 4
Taiyuan 4
Bologna 3
Borås 3
Brescia 3
Falls Church 3
Hangzhou 3
Kraków 3
Lanzhou 3
Luxembourg 3
Mumbai 3
Naples 3
Philadelphia 3
Prata Di Pordenone 3
Reggio Nell'emilia 3
Rubiera 3
Savignano sul Rubicone 3
Shaoxing 3
Trento 3
Washington 3
Xian 3
Auburn Hills 2
Bari 2
Bastiglia 2
Bergamo 2
Carpenedolo 2
Casalgrande 2
Chongqing 2
Concordia sulla Secchia 2
Düsseldorf 2
Huizen 2
Katowice 2
Leicester 2
Lugo 2
Mestre 2
Montegaldella 2
Montreal 2
Mountain View 2
Múggia 2
Napoli 2
Totale 2.975
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 191
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 125
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 113
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 99
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 94
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 93
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 92
Characterization of gefitinib uptake in NSCLC cell lines 91
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 88
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 87
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 85
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 84
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 82
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 82
Physico-chemical characterization and biological evaluation of two fibroin materials 78
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 78
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 78
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 77
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 77
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 77
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 76
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 76
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 76
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 73
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 73
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 73
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 73
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 72
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 72
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 72
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 70
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 68
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 67
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 65
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 65
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 64
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 64
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 64
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 62
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 61
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 59
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 57
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 57
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 56
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 56
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 56
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 55
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 54
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 52
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 52
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 52
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 51
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 51
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 51
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 50
Synergistic activity of letrozole and sorafenib on breast cancer cells 49
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 49
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 49
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 49
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 48
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 47
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 47
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 46
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 45
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 43
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 42
Immunotherapeutic approaches in malignant pleural mesothelioma 41
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 40
Targeting FGFR1 pathway in squamous cell lung cancer 39
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 38
New therapeutic strategies for malignant pleural mesothelioma 38
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 36
null 31
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 25
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 24
Totale 4.892
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.538
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.538
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019163 0 0 0 0 0 25 13 5 22 8 83 7
2019/20201.021 148 156 45 21 67 127 159 42 94 68 38 56
2020/2021552 13 49 38 37 59 16 48 30 86 23 113 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.823 147 183 121 118 159 196 29 148 598 14 81 29
2023/2024243 45 53 32 49 56 8 0 0 0 0 0 0
Totale 4.892